	Application No.	Applicant(s)	
Notice of Allowability	09/738,847	DENG ET AL.	
	Examiner	Art Unit	
	J. Eric Angell	1635	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in to or other appropriate community of the community	this application. If not includ lication will be mailed in due	led course. THIS
 2. The allowed claim(s) is/are 36,51 and 52. 3. The drawings filed on 15 December 2000 are accepted by 4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 	der 35 U.S.C. § 119(a)-(d) or (f).	
		No	
2. Copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of			
each sheet. 9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR T			Note the
Attachm nt(s)			
1 ☐ Notice of References Cited (PTO-892) 3 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5 ☑ Information Disclosure Statements (PTO-1449), Paper No. 7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	4⊠ Interview 6⊠ Examiner	Informal Patent Application (Summary (PTO-413), Paper 's Amendment/Comment 's Statement of Reasons for	r No. <u>1 12</u> 9
		J. Eric Angell	

Application/Control Number: 09/738,847

Art Unit: 1635

EXAMINER'S AMENDMENT

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/12/2003 has been entered.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Christine Lee on 10/29/03.

The application has been amended as follows:

Claim 36 has been amended to read:

A method of making an attenuated FIV-141 virus that replicates upon entry into a host cell but which exhibits significantly reduced infectivity to feline T lymphocytes relative to wild type FIV-141 virus comprising mutating by deletion in the ENV gene of the wild type virus.

(It is noted that the only change in claim 36 above is the changing of the word "an" to "the" in the phrase "by deletion in the ENV gene" in the last line of claim 36 above.)

Page 2

Page 3

Claim 61 has been cancelled by Examiner's Amendment, authorized by the attorney of

record.

Additionally, claims 45-48 and claim 70 have been cancelled by Examiner's

Amendment as they are drawn to a non-elected invention. The Election was made without

traverse in the paper filed May 28, 2002.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to J. Eric Angell whose telephone number is (703) 605-1165. The

examiner can normally be reached on M-F (8:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone number for

the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

DAVET NOUTER

J. Eric Angell, Ph.D.

AU 1635